In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Tr em cng khng c b sung betaine tr khi c s ch nh ca bc s iu tr mt s bnh, thng l cc bnh di truyn lin quan n chc nng gan b trc trc
[28] Constipation a recognised side effect of GLP-1-based therapies can also temporarily add to measured weight
F., Mnnich, M., Czirr, E., Hollemann, T
Availability: In stock Product Description BPC-157 (Body Protection Compound-157) is een synthetisch peptide afgeleid van een van nature voorkomende eiwitsequentie in maagweefsel
The EU Omnibus Directive requires that promotional prices reference the lowest price from the prior 30 days